Skip to content
2026 OSHP Fall Seminar Email Header

2026 Fall Seminar ACPE Accreditation Information

ACPE Continuing Pharmacy Education
This program has been planned and implemented in accordance with the policies of the Accreditation Council on Pharmacy Education (ACPE) through the joint sponsorship of the Oregon State University College of Pharmacy and the Oregon Society for Health-System Pharmacists (OSHP). The Oregon State University College of Pharmacy is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians will receive ACPE Continuing Education Credit. An NABP e-Profile ID is required to receive CPE hours. An NABP e-Profile ID can be obtained at MyCPEMonitor.net. Statement of Credit shall be issued only after successful completion of the program. Successful completion is defined as: 1) Attending, in its entirety, the CPE activity or activities; 2) Participation in the pre-test administered by the presenter; 3) Completion of the online activity evaluation and post-test located at: http://pharmacy.oregonstate.edu/ce within 14 days of program attendance.

Statements of Credit will be uploaded to each participant’s NABP e-profile automatically within 48 hours of successful program completion. It is the participant’s responsibility to complete the online components within 14 days of program attendance to ensure awarding of credit. It is the participant's responsibility to check CPE Monitor and ensure credits have successfully uploaded.

Target Audience: Pharmacists and Pharmacy Technicians

Total Credits Available: 6 contact hours for up to 0.6 CEUs

Conflict of Interest Disclosures: None of the speakers or planners for this program have any financial relationships with ineligible companies to disclose.

Title: Measles Update - 2026
UAN: 0036-9999-26-221-L01-P and 0036-9999-26-222-L01-T
Time: 8:00 - 9:00 am
Speakers: Lorne Walker, MD, PhD, Oregon Health & Science University, Associate Professor of Pediatrics, Division of Pediatric Infectious Diseases
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.0 (0.1 CEUs)

Learning Objectives:

  1. Interpret the current state of measles infection and transmission in the US
  2. Critically appraise the groups and ideas currently influencing the discussion of measles in the US
  3. (RPh Only) Recommend the correct preventative and therapeutic strategies for measles virus infection
  4. (CPT Only) Identify the correct preventative and therapeutic strategies for measles virus infection

Title: Acute Ischemic Stroke: 2026 Guideline Updates
UAN:     0036-9999-26-223-L01-P/T
Time: 9:35 – 10:05 am
Speakers: Brendon Blaustein, PharmD, BCPS, BCCCP, Oregon Health & Science University, Clinical Pharmacist, Neurology/Neurosurgery
Activity-Type: Knowledge-based
Credit Hours: 0.5 (0.05 CEUs)

Learning Objectives:

  1. Identify key updates in the 2026 AHA/ASA Guideline for the Early Management of Patients with Acute Ischemic Stroke (AIS)
  2. Describe patient eligibility criteria, contraindications, and treatment considerations for intravenous thrombolytic therapy in AIS
  3. Differentiate the roles of tenecteplase, alteplase, and endovascular thrombectomy in the management of patients with AIS
  4. Recognize current guideline recommendations for early blood pressure management following AIS
  5. Identify current guideline recommendations for the use and timing of initiation of antiplatelet and anticoagulant therapy following AIS

Title: When Creatinine Doesn’t Cut It: Cystatin C in Drug Dosing
UAN: 0036-9999-26-224-L01-P and 0036-9999-26-225-L01-T
Time: 10:05 - 10:35 am
Speakers: Tianna Leitch, PharmD, Oregon Health & Science University, Critical Care Clinical Pharmacist
Activity-Type: Application for RPh; Knowledge for CPT
Credit Hours: 0.5 (0.05 CEUs)

RPh Learning Objectives:

  1. Identify patient populations and clinical situations in which creatinine-based estimates of kidney function may be less reliable and cystatin C may provide additional information
  2. Apply cystatin C–based kidney function estimates to medication dosing decisions using patient-specific clinical scenarios
  3. Develop a practical approach for incorporating cystatin C into renal dosing recommendations

CPT Learning Objectives:

  1. Describe the role of creatinine and cystatin C as laboratory markers used to assess kidney function.
  2. Recognize situations in which a cystatin C result may be relevant to medication dosing and renal medication safety.
  3. Differentiate between creatinine- and cystatin C–based kidney function results and identify discrepancies that should be brought to the pharmacist’s attention

Title: Erythro-cation!
UAN: 0036-9999-26-226-L05-P and 0036-9999-26-227-L05-T
Time: 10:55 – 11:55 am
Speakers: Susie Jiing, PharmD, BCOP, Oregon Health & Science University, Clinical Pharmacy Manager, Oncology; Shiela McCollam, PharmD, BCOP, Oregon Health & Science University, Oncology Clinical Supervisor
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.0  (0.1 CEUs)
State Requirement: Patient Safety

Learning Objectives:

  1. Describe the role of the clinical pharmacy agreement and/or collaborative drug therapy management policy as defined by the Oregon Board of Pharmacy
  2. Describe the background rationale for the OHSU ESA Use Restriction and Dosing Policy in the ambulatory setting
  3. Illustrate the process of the OHSU ESA Use Restriction and Dosing Policy
  4. (RPh Only) Analyze ESA appropriateness based on labs and clinical findings

Title: Mental Health and Wellbeing for Healthcare Professionals: The Neurobiology of Stress, and Complementary and Alternative Modalities to Build Resilience
UAN: 0036-9999-26-228-L99-P/T
Time: 12:30 – 1:30 pm
Speakers: Gary Runyon, PharmD, RYT-500, Oregon Board of Pharmacy, Executive Director
Activity-Type: Application-based
Credit Hours: 1.0 (0.1 CEUs)

Learning Objectives:

  1. Describe the neurobiological mechanisms of chronic stress, including sympathetic nervous system overdrive and allostatic load
  2. Distinguish between passive relaxation and active neuro-regulatory interventions in the context of mitigating professional burnout
  3. Apply targeted breathwork techniques (e.g., box breathing, cyclic sighing) to immediately interrupt automatic stress loops
  4. Evaluate the clinical utility of complementary modalities (yoga, clinical hypnosis, Transcendental Meditation) for long-term nervous system regulation and structural brain remodeling
  5. Formulate a personal resilience strategy by integrating data-backed neuro-regulatory tools to counter systemic workplace stress

Title: The Case for Consensus: New Guidance and Evidence for the Management of MSSA Bacteremia
UAN: 0036-9999-26-229-L01-P and 0036-9999-26-230-L01-T
Time: 2:00 – 3:00 pm
Speakers: Mara Gosch, PharmD, Oregon Health & Science University, PGY2 Critical Care Resident; Anna Sandstrom, PharmD, Oregon Health & Science University, PGY2 Infectious Disease Resident
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.0 (0.1 CEUs)

Learning Objectives:

  1. Identify factors that inform newly updated risk stratification in the initial evaluation and management of Staphylococcus aureus bacteremia (SAB)
  2. Evaluate and compare cefazolin and antistaphylococcal penicillins (ASPs) for the treatment of methicillin-susceptible (MSSA) bacteremia
  3. Evaluate and compare penicillin and antistaphylococcal penicillins (ASPs) for the treatment of penicillin-susceptible (PSSA) bacteremia
  4. (RPh Only) Select appropriate step-down oral antibiotic therapy for a patient with PSSA or MSSA bacteremia

Title: Updates in Dyslipidemia Management: New Drugs, New Trials, New Guidelines, Oh My!
UAN: 0036-9999-26-231-L01-P and 0036-9999-26-232-L01-T
Time: 3:00 – 4:00 pm
Speakers: Bruce A. Warden, PharmD, Oregon Health & Science University, Clinical Pharmacist
Activity-Type: Application for RPh; Knowledge for CPT
Credit Hours: 1.0 (0.1 CEUs)

RPh Learning Objectives:

  1. Identify patients at high risk for ASCVD and with clinical ASCVD requiring lipid screening and ASCVD risk stratification
  2. Summarize the impact of LDL-C on ASCVD development and the importance of achieving LDL-C thresholds to reduce the risk of ASCVD events
  3. Apply current guideline-based treatment recommendations for patients at high risk for ASCVD and with clinical ASCVD

CPT Learning Objectives:

  1. Explain the risks for ASCVD
  2. Summarize the impact of LDL-C on ASCVD development and the importance of achieving LDL-C thresholds to reduce the risk of ASCVD events
  3. Discuss current guideline-based treatment recommendations for patients at high risk for ASCVD and with clinical ASCVD

 

Scroll To Top